A Novel, Low-Cost Glaucoma Calculator to Identify Glaucoma Patients and Stratify Management

Glaucoma is a leading cause of preventable blindness globally. Nearly, half of the patients who have glaucoma in the United States are unaware of their diagnosis, and this number is far greater in resource poor areas. The risk of progressive and irreversible loss of vision is decreased with an early diagnosis, and better access to treatment is vital to improve the visual outcome for patients. We therefore postulated that a minimally invasive, low-cost calculator used to predict the risk of glaucoma and inform the course of follow-up care will improve patient prognosis. We retrospectively examined data from 104 eyes of patients who underwent a complete ocular examination, visual field, and corneal pachymetry at Advanced Eye Care of New York (54 with glaucoma and 50 controls). Receiver operating curves (ROC) were utilized to determine the correct glaucoma classification rates of the Laroche glaucoma calculator (Range −3 to 18), a novel tool that combines age, intraocular pressure (IOP), and central corneal thickness (CCT) into a composite metric. Additionally, we compared the discriminatory power of this calculator to age, intraocular pressure (IOP), and central corneal thickness (CCT) separately. A score of greater than or equal to 6 on the Laroche glaucoma calculator (sensitivity 90.74%, specificity 64.00%, correct classification 77.88%) optimizes the accuracy of this tool. Compared to IOP (Area Under the Curve (AUC) = 0.72, chi2 = 4.21, p=0.04) and CCT (AUC = 0.53), chi2 24.72 p < 0.001), the Laroche glaucoma calculator (AUC = 0.81) was significantly better at discriminating against glaucoma patients vs. controls. These results demonstrate that the Laroche calculator is a novel, effective tool for identifying glaucoma, and it may provide a low-cost risk stratification tool, particularly in areas with limited resources.

[1]  C. Doré,et al.  Risk factors for visual field deterioration in the United Kingdom Glaucoma Treatment Study. , 2020, Ophthalmology.

[2]  I. Benseñor,et al.  Validating the Framingham Hypertension Risk Score: A 4‐year follow‐up from the Brazilian Longitudinal Study of the Adult Health (ELSA‐Brasil) , 2020, Journal of clinical hypertension.

[3]  N. Rohatgi Perioperative Risk Calculators and the Art of Medicine. , 2019, JAMA internal medicine.

[4]  T. Yoo,et al.  Framingham risk score and risk of incident chronic kidney disease: A community-based prospective cohort study , 2019, Kidney research and clinical practice.

[5]  M. Kass,et al.  What We Have Learned From the Ocular Hypertension Treatment Study. , 2018, American journal of ophthalmology.

[6]  S. Ahmad Glaucoma suspects: A practical approach , 2018, Taiwan journal of ophthalmology.

[7]  C. McMonnies Glaucoma history and risk factors , 2016, Journal of optometry.

[8]  Michael V. Boland,et al.  Prevalence of Glaucoma in the United States: The 2005–2008 National Health and Nutrition Examination Survey , 2016, Investigative ophthalmology & visual science.

[9]  Ching-Yu Cheng,et al.  Author reply: To PMID 24974815. , 2015, Ophthalmology.

[10]  R. Luben,et al.  The EPIC-Norfolk Eye Study: rationale, methods and a cross-sectional analysis of visual impairment in a population-based cohort , 2013, BMJ Open.

[11]  Robert Ritch,et al.  A validated risk calculator to assess risk and rate of visual field progression in treated glaucoma patients. , 2012, Investigative ophthalmology & visual science.

[12]  E. Mascha,et al.  Development and Validation of a Risk Quantification Index for 30-Day Postoperative Mortality and Morbidity in Noncardiac Surgical Patients , 2011, Anesthesiology.

[13]  Michael V. Boland,et al.  The Impact of Risk Calculation on Treatment Recommendations Made by Glaucoma Specialists in Cases of Ocular Hypertension , 2008, Journal of glaucoma.

[14]  Felipe A Medeiros,et al.  Diagnostic tools for calculation of glaucoma risk. , 2008, Survey of ophthalmology.

[15]  Joseph Caprioli,et al.  The importance of rates in glaucoma. , 2008, American journal of ophthalmology.

[16]  M. C. Leske,et al.  Predictors of long-term progression in the early manifest glaucoma trial. , 2007, Ophthalmology.

[17]  R. D'Agostino,et al.  Validated prediction model for the development of primary open-angle glaucoma in individuals with ocular hypertension. , 2007, Ophthalmology.

[18]  B. Munoz,et al.  The prevalence of open-angle glaucoma among blacks and whites 73 years and older: the Salisbury Eye Evaluation Glaucoma Study. , 2006, Archives of ophthalmology.

[19]  G. Cioffi,et al.  The Probability of Glaucoma From Ocular Hypertension Determined by Ophthalmologists in Comparison to a Risk Calculator , 2006, Journal of glaucoma.

[20]  Douglas R. Anderson,et al.  Management of ocular hypertension: a cost-effectiveness approach from the Ocular Hypertension Treatment Study. , 2006, American journal of ophthalmology.

[21]  Ralph B D'Agostino,et al.  Framingham risk score and prediction of lifetime risk for coronary heart disease. , 2004, The American journal of cardiology.

[22]  M. C. Leske,et al.  Prevalence of open-angle glaucoma among adults in the United States. , 2004, Archives of ophthalmology.

[23]  A. Investigators The Advanced Glaucoma Intervention Study (AGIS): 11. Risk factors for failure of trabeculectomy and argon laser trabeculoplasty. , 2002, American journal of ophthalmology.

[24]  E. DeLong,et al.  Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.

[25]  H Goldmann,et al.  Open-angle glaucoma. , 1972, The British journal of ophthalmology.